Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
Hyde
C
C
Department of Public Health and Epidemiology, University of Birmingham, UK.
Wake
B
B
Bryan
S
S
Barton
P
P
Fry-Smith
A
A
Davenport
C
C
Song
F
F
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine